anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Dose escalation for lintuzumab-Ac225 will be conducted according to a 3+3 design. CLAG-M chemotherapy will be administered at a fixed dose and schedule (cladribine 5mg/m\^2/day IV over two hours on days 2-6; cytarabine 2 gm/m\^2/day IV over four hours on days 2-6, starting two hours after the cladribine infusion is complete; mitoxantrone 10mg/m\^2/day IV on days 2-4 and G-CSF at a dose of 300 µg on days 1-6). Lintuzumab-Ac225 will be administered as a single dose on day 8 of therapy.
OBJECTIVES: The choice of surgical technique for aponeurectomy in Dupuytren's disease is controversial due to varying outcomes and complication rates. The Malingue plasty has shown mathematical and mechanical advantages, but long-term efficacy and results compared to other techniques have never been reported. This study aimed to evaluate the long-term functional, esthetic and recurrence outcomes of Malingue plasty in Dupuytren's disease.
MATERIAL AND METHODS: The study included patients who underwent aponeurectomy with Malingue plasty performed by a highly experienced surgeon between January 2014 and December 2016, with a minimum follow-up of 5 years. Preoperative records were analyzed. At follow-up, extension lag was analyzed in each joint (metacarpophalangeal, proximal interphalangeal and distal interphalangeal) in each operated finger, as well as signs of recurrence or extension of the disease. Function and esthetics were assessed using the QuickDASH (Disabilities of the Arm, Shoulder and Hand) questionnaire and the Michigan Hand Outcomes Questionnaire.
RESULTS: Out of 107 eligible patients, 55 were included in the study after exclusions and loss to follow-up. Three patients required revision surgery for recurrence during follow-up. All preoperative deformities of the proximal interphalangeal and metacarpophalangeal joints were corrected postoperatively, and no intraoperative or postoperative complications occurred. Mean extension deficit at follow-up was 18.1 °. Only the little finger showed significant loss of correction (p = 0.02). Mean QuickDASH score was 13.2 and the overall Michigan Hand Outcomes Questionnaire score was 91.8%. Recurrence affected 50% of patients according to the Leclercq criteria and 27.5% according to the Felici criteria.
CONCLUSION: Although Malingue plasty did not improve the recurrence rate in Dupuytren's disease compared with other techniques, its advantages in terms of functional improvement and complications make it an interesting surgical option.
Objective: To describe the population and area distribution differences in the prevalence of urinary incontinence in middle-aged and elderly adults in 10 areas in China. Methods: A total of 24 913 participants aged 45-95 years who completed the third resurvey of China Kadoorie Biobank during 2020-2021 were included. The prevalence of urinary incontinence was assessed by an interviewer-administered questionnaire, and urinary incontinence was classified as only stress urinary incontinence, only urgency urinary incontinence and mixed urinary incontinence. The prevalence of urinary incontinence and its subtypes were reported by sex, age and area, and the severity of urinary incontinence and treatment were described. Results: The average age of the participants was (65.4±9.1) years. According to the seventh national census data in 2020, the age-standardized prevalence rates of urinary incontinence was 25.4% in women and 7.0% in men. The age-standardized prevalence rates of only stress, only urgency and mixed incontinence were 1.7%, 4.2% and 1.2% in men and 13.5%, 5.8% and 6.1% in women, respectively. The prevalence rates of urinary incontinence and all subtypes in men and the prevalence of urinary incontinence and all subtypes except only stress urinary incontinence in women all increased with age (P<0.001). After adjusting for age, the prevalence of urinary incontinence in both men and women were higher in rural area than in urban area (P<0.001). The treatment rates in men and women with urinary incontinence were 15.4% and 8.5%, respectively. Conclusions: The prevalence of urinary incontinence was high in middle-aged and elderly adults in China, and the prevalence rate was higher in women than in men, but the treatment rate of urinary incontinence was low.
A composition for oral, parenteral or rectal administration for use in the treatment of animals before mating to influence the sex and for the qualities of the issue, comprises a mineral constituent, a vitamin constituent and royal jelly.  The mineral constituent consists of two or more metals e.g. gold, silver, iron, copper, sodium, zinc, cobalt, magnesium, manganese and nickel provided in a form suitable for assimilation by the animal being treated e.g. as water-soluble salts.  The vitamin constituent means a mixture of vitamins e.g. Vitamins A, D, E, K, C and B.  Optional ingredients are corn germ oil, novocaine and its derivatives, cocaine, desoxy ribonucleic acid, hormones, antibiotics, sulphonamides and living cells.  The composition may be used as a solution in water, alcohol or oil but may be mixed with a solid carrier.  Concentrates may be added to the animal food or drink.
In the sedation group, 1 mcg/kg IV fentanyl and 1 mg/kg IV ketamine were administered at induction, and 30-50 mg IV propofol was added if necessary to maintain anesthesia. The Montgomery-Asberg Depression Rating Scale (MADRS), the Hamilton Anxiety Rating Scale (HAM-A), and the Beck Scale for Suicide Ideation (BSSI) were administered preoperatively and on postoperative day one by a psychiatrist.
Patients receive cisplatin IV over 1 hour on day 1 and veliparib PO BID on days 1-14. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
BACKGROUND AND OBJECTIVES: Behavioral and neuropsychiatric symptoms are frequent in patients with genetic frontotemporal dementia (FTD). We aimed to describe behavioral and neuropsychiatric phenotypes in genetic FTD, quantify their temporal association, and investigate their regional association with brain atrophy.
METHODS: We analyzed data of pathogenic variant carriers in the chromosome 9 open reading frame 72 (c9orf72), progranulin (GRN), or microtubule-associated protein tau (MAPT) gene from the Genetic Frontotemporal dementia Initiative cohort study that enrolls both symptomatic pathogenic variant carriers and first-degree relatives of known carriers. Principal component analysis was performed to identify behavioral and neuropsychiatric clusters that were compared with respect to frequency and severity between groups. Associations between neuropsychiatric clusters and MRI-assessed atrophy were determined using voxel-based morphometry. We applied linear mixed effects and generalized linear mixed effects models to assess the longitudinal course of symptoms.
RESULTS: A total of 522 participants were included: 221 c9orf72 (138 presymptomatic), 213 GRN (157 presymptomatic), and 88 MAPT (62 presymptomatic) pathogenic variant carriers. Principal component analysis revealed 5 phenotypic clusters (67.6% of variance), labeled diverse behavioral, affective, psychotic, euphoric/hypersexual, and tactile hallucinations phenotype. In participants presenting behavioral or neuropsychiatric symptoms, affective symptoms were most frequent across groups (83.6%-88.1%), followed by diverse behavioral symptoms (68.4%-77.9%). In c9orf72 and GRN pathogenic variant carriers, psychotic symptoms (32.0% and 19.4%, respectively) were more frequent than euphoric/hypersexual symptoms (28.7% and 14.2%, respectively), which was the other way around in MAPT pathogenic variant carriers (28.6% and 23.8%). Although diverse behavioral symptoms were associated with gray and white matter frontotemporal atrophy, only a small atrophy cluster in the right thalamus was associated with psychotic symptoms. Euphoric/hypersexual symptoms were associated with atrophy in mesial temporal lobes, basal forebrain structures, and the striatum (p < 0.05). Estimated time to symptom onset, genetic group, education, and sex influenced behavioral and neuropsychiatric symptoms (p < 0.05). Particularly, in c9orf72 pathogenic variant carriers, psychotic symptoms may be starting decades before recognition of onset of illness.
DISCUSSION: We identified multiple clusters of behavioral and neuropsychiatric symptoms in participants with genetic FTD that relate to distinct cerebral atrophy patterns. Their severity depends on time, affected gene, sex, and education. These clinical-genetic associations can guide diagnostic evaluations and the design of clinical trials for new disease-modifying and preventive treatments.
Analogs of keratinocyte growth factor (KGF) are obtained by modification of one or several amino acids in the range of 32-55 amino acids in the sequence of SEQ ID NO:2. The rest of cysteine in the positions of 32 and 46 is deleted of modified by other amino acid. The expression vector containing recombinant nucleic acid coding the analogue KGF is transformed in the cells of E.coli. The transformed strain of E.coli is cultivated and the analogue KGF is obtained. Analogs of KGF are used in the pharmaceutical composition for stimulating the growth of epithelial cells. The invention allows obtaining analogs of KGF with high resistance in storage.
PURPOSE:A salicylate salt and/or bile salt are used to solublize hard-soluble medicines and a reductive sulfur compound is added to give the titled stabilized composition. CONSTITUTION:The compound of the formula is solubilized using a salicylate salt such as sodium salicylate and/or a bile salt such as sodium deoxycholate, and a reductive sulfur compound such as glutathion or sodium metabisulfite, or an isolation agent such as ethylenediaminetetraacetic disodium salt (EDTA.2 Na) or EDTA.2Na.Ca to give a stabilized composition. The amount of the compound is 10-200ml/ml of water or 0.6-20pts.wt. of other additives including salicylic acid per 1pt.wt. of the compound of the formula. The dose is 1-10ml/ person/administration as an injection solution, when needed, 100-500ml are intravenously dripped. The addition of a stabilizer enables the medicines to be stored as a freezedried preparation for a long period of time.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to compounds of the formula: A-B-D-E-F-G where radical values are given in description in all their stereoisomeric forms and their mixtures in all ratios and their physiologically acceptable salts. Compounds exhibit high antagonistic activity with respect to vitronectin receptors and they are inhibitors of bone resorption. Invention describes also pharmaceutical preparations showing antagonistic activity with respect to vitronectin receptor and comprising compounds indicated above. EFFECT: improved method of preparing, valuable medicinal properties. 8 cl, 7 ex
PURPOSE:To safely obtain N-solanesyl-N,N'-bis(3,4-dimethoxybenzyl) ethylenediamine through a short process by reaction of e.g. a solanesyl halide with a reaction product from veratraldehyde and ethylenediamine. CONSTITUTION:Firstly, a reaction is made at 10 deg.C to room temperature between a compound of formula I and ethylenediamine at a molar ratio of 2:1 in a solvent such as methanol or THF either in the presence of NaBH4 or under hydrogenation conditions using Pd catalyst to prepare a compound of formula II. Thence, this compound is reacted with a solanesyl halide or solanesyl tosylate at a molar ratio of (3-5):1 at 10 deg.C to room temperature in a solvent to obtain the objective compound of formula III. In the latter reaction, to suppress the formation of a byproduct, a compound of formula IV, it is preferable that a great excess of the compound of the formula II be used. The present compound of the formula III is useful as a medicine having carcinostatic activity- enhancing effect, carcinostatic tolerance-surmounting effect, antiviral effect, etc.
PURPOSE:To manually process the radiation pictures with high efficiency and without hindering the continuous routine processing jobs, by displaying two images related to two picture data on both routine and manual processes in the difference display areas of the same picture monitor. CONSTITUTION:The routine processing picture data is stored temporarily in a temporary storing frame memory 13. Then this picture data is transferred to a picture file memory 7 as soon as the same routine manual processing is through. Thus the manual processing picture data is obtained. Then two images related to said two picture data are simultaneously displayed in the different designated areas R and M of the same picture monitor 10. In such a way, the radiation pictures can be manually processed with high efficiency and without hindering the continuous routine processing jobs.
The present invention discloses enema physic liquor for curing diarrhea, which mainly contains pipemidic acid tablets. The present invention can be a mixture of pipemidic acid, physiological saline and alkaline, and can also be a mixture of pipemidic acid and glycerol. The present invention changes administration routes, and exerts higher sterilization action and bacteriostatic action than systemic administration because medicine can directly act on diseased parts. Simultaneously, the present invention avoids toxic effects and side effects of antibiotic by systemic administration. The present invention has obvious curative effects and high cure rate to bacillary dysentery, enteritis, ulcerative colitis, etc. which takes diarrhea as main symptoms.
The purpose of this study is to examine how the amount and distribution of weight on the pelvis affects how people walk. The investigators two factors, weight and placement. They are examining how these factors affect muscle activation, joint motions and foot forces. The investigators plan to recruit 40 healthy adult individuals. Each of the 20 experimental conditions (3x3 factorial and one control condition with no weight) will be recorded immediately in a single session. The investigators hypothesize that weight amount, gait speed and weight distribution will all affect how people walk, which will lead towards optimized design of hip exoskeletons.
A Pan-Canadian, Phase 3, open-label, randomized trial of bone marrow aspirate concentrate (BMAC) administration in patients with mild to severe knee OA. A total of 374 eligible patients will be randomized to BMAC or Standard of Care (SOC). Patients randomized to the interventional arm (BMAC) will have a sample of bone marrow taken (from their pelvic region) and processed at the bedside for immediate delivery back to the patient via intra-articular (IA) injection into one or both knees.

All randomized patients will be followed for 48 weeks. Blood will be collected at scheduled visits for analysis. Adverse events will be monitored throughout the trial. Assessments will be performed by physical exam and standardized questionnaires related to the physical function, health, and pain of each participant will be conducted.
<P>PROBLEM TO BE SOLVED: To provide a new leptospiral protein, to provide a gene encoding the same, to provide a new medicament having infection preventive action against leptospiral disease, and to provide a diagnostic kit for the leptospiral disease.  <P>SOLUTION: This leptospiral protein comprises a leptospiral protein LigA-m or a leptospiral protein LigB-m. The gene encodes the protein. The medicament contains the leptospiral protein LigA-m or LigB-m as an active ingredient and has the infection preventive action against the leptospiral disease. The diagnostic kit for the leptospiral disease contains the protein.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Rebless® (H-ROBOTICS, KOREA) is a knee or ankle robot for range of motion (ROM) and strength training that can operate in passive or active mode in knee or ankle flexion and extension. The patients underwent 30 min of robot training using Rebless® with 30 min conventional therapy, 5 days a week for 8 weeks.
VB10.16 vaccinations. 11 intramuscular (i.m.) vaccinations for up to 48 weeks from first vaccination. 5 vaccinations of 3 mg VB10.16 during the first 12 weeks, followed by vaccination every 6 weeks for up to 48 weeks + Atezolizumab (1200 mg) intravenous (i.v.) infusion every 3 weeks.
SMART emphasizes top-down processing by targeting focused attention, assimilation of information, and mental flexibility and innovation, all higher-order cognitive functions driven by the frontal lobes. SMART was delivered in small groups (n = 2 to 8) consisting of two 3-hour sessions over two days, followed by one 3-hour session a month later. Overall, sessions focused on strategic attention, integrative reasoning, and cognitive control functions (Chapman, 2014). Training consists of initial sessions of skills training with the one-month follow-up session being a "booster session" consisting of review. We modified the training such that all sessions included skills training with briefer review. The first two sessions consisted of strategic attention and integrated reasoning and the final session discussed innovation.
Participants will ingest an active supplement containing beta-alanine for a period of maximum 6 months. During the whole period, participants will take part in a structured program of PMFT. After first month, the participants will undergo radical prostatectomy.
Patients receive 400 mg oral sorafenib twice daily on days 1-28. Patients experiencing disease progression cross over to Arm II.
OBJECTIVES: The severity of fatigue in RA has improved very little in recent decades, leaving a large unmet need. Fortunately, not all RA patients suffer from persistent fatigue, but the subgroup of patients who suffer the most is insufficiently recognizable at diagnosis. As disease activity is partly coupled to fatigue, DAS components may associate with the course of fatigue. We aimed to identify those RA patients who remain fatigued by studying DAS components at diagnosis in relation to the course of fatigue over a 5-year follow-up period in two independent early RA cohorts.
METHODS: In all, 1560 consecutive RA patients included in the Leiden Early Arthritis Cohort and 415 RA patients included in the tREACH trial were studied. Swollen joint count, tender joint count, ESR and Patient Global Assessment (PGA) [on a Visual Analogue Scale (VAS)] were studied in relation to fatigue (VAS, 0-100 mm) over a period of 5 years, using linear mixed models.
RESULTS: Higher tender joint count and higher PGA at diagnosis were associated with a more severe course of fatigue. Furthermore, patients with mono- or oligo-arthritis at diagnosis remained more fatigued. The swollen joint count, in contrast, showed an inverse association. An investigation of combinations of the aforementioned characteristics revealed that patients presenting with mono- or oligo-arthritis and PGA ≥ 50 remained the most fatigued over time (+20 mm vs polyarthritis with PGA < 50), while the DAS course over time did not differ. This subgroup comprised 14% of the early RA population. Data from the tREACH trial showed similar findings.
CONCLUSION: The RA patients who remain the most fatigued were those characterized by mono- or oligo-arthritis and high PGA (VAS ≥ 50) at diagnosis. This understanding may enable early-intervention with non-pharmacological approaches in dedicated patient groups.
OBJECTIVES: A growing body of data indicates that extracranial carotid artery disease (ECAD) can contribute to cognitive impairment. However, there have been mixed reports regarding the benefit of carotid endarterectomy (CEA) as it relates to preserving cognitive function. In this work, diffusion magnetic resonance imaging (dMRI) and neurocognitive testing are used to provide insight into structural and functional brain changes that occur in subjects with significant carotid artery stenosis, as well as changes that occur in response to CEA.
MATERIALS AND METHODS: The study design was a prospective, non-randomized, controlled study that enrolled patients with asymptomatic carotid stenosis. Thirteen subjects had severe ECAD (≥70% stenosis in at least one carotid artery) and were scheduled to undergo surgery. Thirteen had asymptomatic ECAD with <70% stenosis, therefore not requiring surgery. All subjects underwent neurocognitive testing using the Montreal Cognitive Assessment test (MoCA) and high angular resolution, multi-shell diffusion magnetic resonance imaging (dMRI) of the brain at baseline and at four-six months follow-up. Changes in MoCA scores as well as in Fractional anisotropy (FA) along the hippocampus were compared at baseline and follow-up.
RESULTS: At baseline, FA was significantly lower along the ipsilateral hippocampus in subjects with severe ECAD compared to subjects without severe ECAD. MoCA scores were lower in these individuals, but this did not reach statistical significance. At follow-up, MoCA scores increased significantly in subjects who underwent CEA and remained statistically equal in control subjects that did not have CEA. FA remained unchanged in the CEA group and decreased in the control group.
CONCLUSIONS: This study suggests that CEA improves cognition and preserves hippocampal white matter structure compared to control subjects not undergoing CEA.
FIELD: genetic engineering, immunology, molecular biology, veterinary science. SUBSTANCE: invention describes novel antigenic polypeptide, its fragments and variants able to produce protective immune response in body infection with Echinococcus granulosis. Invention reports nucleotide sequence encoding indicated forms of antigenic polypeptide being insertion of these sequences into corresponding vector systems provides the possibility for preparing novel antigens by method of recombinant DNAs. Invention relates also to development, along with vaccines comprising ready antigenic polypeptide, recombinant viral vaccines including nucleic acid with its expression in the animal body. Proposed vaccines are designated for protection of hosts susceptible to infection with parasites of genus Echinococcus. EFFECT: valuable properties of polypeptide, vaccine. 7 cl, 4 dwg, 5 tbl, 7 ex
Subjects will be asked to sit on the device and the height will be adjusted until the subject's feet are on the floor. The active treatments are individualized, since some subjects will be more sensitive than others. The Emsella chair will be turned on and the setting gradually increased to the subject's sensory threshold; the maximum sensation the subject can tolerate. The setting will be decreased slightly and stay unchanged for the remainder of the treatment. The treatment threshold should be increased with every treatment until the subject reaches 100%.
Acceptance and Commitment Therapy (ACT). Varenicline 2 mg daily for 12 weeks.
PURPOSE:To obtain a hair tonic effective in promoting the nourishing, growth and development of hair and preventing the falling-off of hair, by using a Chinese herb drug such as ONRI-YAKU effective in stimulating the bald part and eliminating the stagnation of blood flow, thereby improving the blood flow in the bald part of thin-haired part of the scalp. CONSTITUTION:The objective hair tonic contains ONRI-YAKU, KAKKETSU-KYOO- YAKU, HOKETSU-YAKU, HOKI-YAKU and SEINETSU-YAKU to improve the blood flow in the bald part or thin-haired part of the scalp. ONRI-YAKU contains HOFUSHI (root of Aconitum carmicaeli) effective in stimulating scalp, warming spleen, stomach and heart and improving blood flow. KAKKETSU-KYOO-YAKU contains TONIN (seed of Prunus persica) and TANJIN (root of Panax ginseng) effective in eliminating the stagnation of blood flow and smoothen the flow. HOKETSU- YAKU contains TOKI (root of Angelica acutiloba) implementing the deficiency of blood and nourishing the body and HOKI-YAKU contains NINJIN (root of Panax ginseng) and OUGI (root of Astragalus membranaceus) implementing the deficiency of vigor and blood and nourishing weakened body. SEINETSU-YAKU contains TOKI (root of Angelica acutiloba) dilating the blood vessel of scalp, conditioning the spleen and stomach and adjusting the automatic nerve.